Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

KalVista Pharmaceuticals (KALV) Receivables - Net (2017 - 2025)

KalVista Pharmaceuticals' Receivables - Net history spans 1 years, with the latest figure at $7.3 million for Q4 2017.

  • On a quarterly basis, Receivables - Net changed N/A to $7.3 million in Q4 2017 year-over-year; TTM through Oct 2017 was $7.3 million, a N/A change, with the full-year FY2017 number at $7.3 million, changed N/A from a year prior.
  • Receivables - Net hit $7.3 million in Q4 2017 for KalVista Pharmaceuticals, roughly flat from $7.3 million in the prior quarter.
  • Over the last five years, Receivables - Net for KALV hit a ceiling of $7.3 million in Q2 2017 and a floor of $7.3 million in Q2 2017.